Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
304
-
Total 13F shares, excl. options
-
56.6M
-
Shares change
-
+1.02M
-
Total reported value, excl. options
-
$4.42B
-
Value change
-
+$78.5M
-
Put/Call ratio
-
0.88
-
Number of buys
-
159
-
Number of sells
-
-129
-
Price
-
$78.08
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q4 2024
367 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q4 2024.
HAEMONETICS CORP - Common Stock (HAE) has 304 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.6M shares
.
Largest 10 shareholders include BlackRock, Inc. (6.16M shares), VANGUARD GROUP INC (5.18M shares), NEUBERGER BERMAN GROUP LLC (4.42M shares), Capital Research Global Investors (4.24M shares), WELLINGTON MANAGEMENT GROUP LLP (3.94M shares), T. Rowe Price Investment Management, Inc. (2.55M shares), STATE STREET CORP (1.95M shares), Thrivent Financial for Lutherans (1.26M shares), GEODE CAPITAL MANAGEMENT, LLC (1.18M shares), and ROYCE & ASSOCIATES LP (1.15M shares).
This table shows the top 304 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.